Hinova Pharmaceuticals Inc. A (688302) - Total Liabilities
Based on the latest financial reports, Hinova Pharmaceuticals Inc. A (688302) has total liabilities worth CN¥255.12 Million CNY (≈ $37.33 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Hinova Pharmaceuticals Inc. A net asset momentum to track the company's year-over-year net asset growth rate.
Hinova Pharmaceuticals Inc. A - Total Liabilities Trend (2019–2024)
This chart illustrates how Hinova Pharmaceuticals Inc. A's total liabilities have evolved over time, based on quarterly financial data.
Hinova Pharmaceuticals Inc. A Competitors by Total Liabilities
The table below lists competitors of Hinova Pharmaceuticals Inc. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AGI Greenpac Limited
NSE:AGI
|
India | Rs11.47 Billion |
|
Compagnie du Bois Sauvage SA
BR:COMB
|
Belgium | €186.49 Million |
|
Smartgen (Zhengzhou) Technology Co. Ltd. A
SHE:301361
|
China | CN¥59.73 Million |
|
Longmaster Information Tech
SHE:300288
|
China | CN¥222.08 Million |
|
Anhui Xinli Finance Co Ltd
SHG:600318
|
China | CN¥2.37 Billion |
|
Zhejiang East Crystal Electronic Co Ltd
SHE:002199
|
China | CN¥257.97 Million |
|
Objective Corporation Ltd
AU:OCL
|
Australia | AU$86.59 Million |
|
ARTRYA Ltd
AU:AYA
|
Australia | AU$2.84 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Hinova Pharmaceuticals Inc. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Hinova Pharmaceuticals Inc. A.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hinova Pharmaceuticals Inc. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hinova Pharmaceuticals Inc. A (2019–2024)
The table below shows the annual total liabilities of Hinova Pharmaceuticals Inc. A from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥169.33 Million ≈ $24.78 Million |
+36.04% |
| 2023-12-31 | CN¥124.47 Million ≈ $18.21 Million |
-16.84% |
| 2022-12-31 | CN¥149.68 Million ≈ $21.90 Million |
-22.68% |
| 2021-12-31 | CN¥193.59 Million ≈ $28.33 Million |
-4.32% |
| 2020-12-31 | CN¥202.33 Million ≈ $29.61 Million |
+151.34% |
| 2019-12-31 | CN¥80.50 Million ≈ $11.78 Million |
-- |
About Hinova Pharmaceuticals Inc. A
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501… Read more